First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors

Status:	Recruiting
Conditions:	Cancer, Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	2/2/2019
Start Date:	April 28, 2017
End Date:	March 20, 2021
Contact:	Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,
Email:	Clinical.Trials@bms.com
Phone:	please email:

Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors

The purpose of this study is to determine whether a Monoclonal Antibody both by itself and in
combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors

Inclusion Criteria:

- For more information regarding Bristol-Myers Squibb Clinical Trial participation,
please visit www.BMSStudyConnect.com

- histologic or cytologic confirmation of a solid tumor that is advanced (metastatic,
recurrent and/or unresectable)

- Eastern Cooperative Oncology Group Performance Status of 0 or 1

- Participants must have received, and then progressed, relapsed, or been intolerant to,
all standard treatment regimens with proven survival benefit in the advanced or
metastatic setting according to tumor type, if such a therapy exists

Exclusion Criteria:

- Participants with primary CNS malignancies, or tumors with CNS metastases as the only
site of disease, will be excluded

- Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior
anti-cancer therapy and initiation of study therapy

- Prior anti-cancer treatments such as chemotherapy, radiotherapy, hormonal, or
immunotherapy (including anti-PD-1/PD-L1) are permitted

Other protocol defined inclusion/exclusion criteria could apply

We found this trial at

sites

Local Institution

116 Pacific Highway
North Sydney, New South Wales 2060

from

North Sydney,